A series of studies have found that first- and second-generation TKIs have achieved improved progression-free survival (PFS) than platinum-based doublet chemotherapy in EGFR-mutated advanced lung cancer (Sequist et al., 2013; Wu et al., 2015). The gene discussed is EGFR; the disease is lung cancer.